RMC-6291 |
| Catalog No.GC69822 |
RMC-6291 is an orally effective covalent inhibitor of KRASG12C(ON). RMC-6291 forms a tri-complex within tumor cells between KRASG12C(ON) and cyclophilin A (CypA). Therefore, RMC-6291 blocks the signaling of KRASG12C(ON) by spatially obstructing the binding of RAS effectors. RMC-6291 produces profound and sustained inhibition of the RAS pathway activity in KRASG12C tumor models.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2641998-63-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Review for RMC-6291
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
Review for RMC-6291
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *